Analgesic Activity of Hexaazaisowurtzitane Derivatives
- Autores: Krylova S.1, Povet’eva T.1, Zueva E.1, Suslov N.1, Amosova E.1, Razina T.1, Lopatina K.1, Rybalkina O.1, Nesterova Y.1, Afanas’eva O.1, Kiseleva E.1, Sysolyatin S.2, Kulagina D.2, Zhdanov V.1
-
Afiliações:
- E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
- Institute of Problems of Chemical and Energetic Technologies, Siberian Division of the Russian Academy of Sciences
- Edição: Volume 166, Nº 4 (2019)
- Páginas: 461-465
- Seção: Article
- URL: https://journals.rcsi.science/0007-4888/article/view/241104
- DOI: https://doi.org/10.1007/s10517-019-04372-9
- ID: 241104
Citar
Resumo
Pronounced analgesic activity of the innovative compound 4-(3,4-dibromthiophencarbonyl)-2,6,8,12-tetraacethyl-2,4,6,8,10,12hexaazatetracyclo[5,5,0,03, 11,05, 9] dodecane (thiowurtzine) was observed in the thermal nociceptive hot plate test and in the acute visceral and somatic deep pain model (acetic acid writhing test). In these experimental models, naloxone-sensitive thiowurtzine-induced analgesia was revealed. The absence of tropism to peripheral opioid receptors in the acetic acid writhing test was demonstrated using naloxone methiodide. Course administration of low-toxic thiowurtzine in effective doses was not associated with ulcerogenic damage to the gastric mucosa in experimental animals.
Sobre autores
S. Krylova
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Autor responsável pela correspondência
Email: krylova5935@gmail.com
Rússia, Tomsk
T. Povet’eva
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: krylova5935@gmail.com
Rússia, Tomsk
E. Zueva
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: krylova5935@gmail.com
Rússia, Tomsk
N. Suslov
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: krylova5935@gmail.com
Rússia, Tomsk
E. Amosova
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: krylova5935@gmail.com
Rússia, Tomsk
T. Razina
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: krylova5935@gmail.com
Rússia, Tomsk
K. Lopatina
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: krylova5935@gmail.com
Rússia, Tomsk
O. Rybalkina
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: krylova5935@gmail.com
Rússia, Tomsk
Yu. Nesterova
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: krylova5935@gmail.com
Rússia, Tomsk
O. Afanas’eva
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: krylova5935@gmail.com
Rússia, Tomsk
E. Kiseleva
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: krylova5935@gmail.com
Rússia, Tomsk
S. Sysolyatin
Institute of Problems of Chemical and Energetic Technologies, Siberian Division of the Russian Academy of Sciences
Email: krylova5935@gmail.com
Rússia, Biysk
D. Kulagina
Institute of Problems of Chemical and Energetic Technologies, Siberian Division of the Russian Academy of Sciences
Email: krylova5935@gmail.com
Rússia, Biysk
V. Zhdanov
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: krylova5935@gmail.com
Rússia, Tomsk
![](/img/style/loading.gif)